Register a trial

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.


With activity expected to increase on the ANZCTR again, there may be extended wait times while we process pending studies, with priority being given to those trials submitted in February. Thank you for your patience.


Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05625399




Registration number
NCT05625399
Ethics application status
Date submitted
15/11/2022
Date registered
22/11/2022

Titles & IDs
Public title
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
Scientific title
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma
Secondary ID [1] 0 0
2022-000575-39
Secondary ID [2] 0 0
CA224-127
Universal Trial Number (UTN)
Trial acronym
RELATIVITY-127
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Melanoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Malignant melanoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Nivolumab + Relatlimab
Treatment: Drugs - rHuPH20

Experimental: Nivolumab + Relatlimab FDC SC -

Active comparator: Nivolumab + Relatlimab FDC IV -


Treatment: Drugs: Nivolumab + Relatlimab
Specified dose on specified days

Treatment: Drugs: rHuPH20
Specified dose on specified days
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time-averaged serum concentration over 28 days after the first dose (Cavgd28) of Nivolumab
Timepoint [1] 0 0
Up to 28 days
Primary outcome [2] 0 0
Trough serum concentration at steady state (Cminss) of Nivolumab
Timepoint [2] 0 0
Up to 4 months
Primary outcome [3] 0 0
Cavgd28 of Relatlimab
Timepoint [3] 0 0
Up to 28 days
Primary outcome [4] 0 0
Cminss of Relatlimab
Timepoint [4] 0 0
Up to 4 months
Secondary outcome [1] 0 0
Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) per RECIST v1.1
Timepoint [1] 0 0
Up to approximately 3 years
Secondary outcome [2] 0 0
Trough serum concentration at Day 28 after the first dose (Cmind28) of Nivolumab and Relatlimab
Timepoint [2] 0 0
Up to 28 days
Secondary outcome [3] 0 0
Peak serum concentration after the first dose (Cmax1) of Nivolumab and Relatlimab
Timepoint [3] 0 0
Up to 28 days
Secondary outcome [4] 0 0
Time to Cmax1 (Tmax1) of Nivolumab and Relatlimab
Timepoint [4] 0 0
Up to 28 days
Secondary outcome [5] 0 0
Peak serum concentration at steady state (Cmaxss) of Nivolumab and Relatlimab
Timepoint [5] 0 0
Up to 4 months
Secondary outcome [6] 0 0
Time-averaged serum concentration at steady state (Cavgss) of Nivolumab and Relatlimab
Timepoint [6] 0 0
Up to 4 months
Secondary outcome [7] 0 0
Duration of Response (DOR) by BICR per RECIST v1.1
Timepoint [7] 0 0
Up to approximately 3 years
Secondary outcome [8] 0 0
Disease Control Rate (DCR) by BICR per RECIST v1.1
Timepoint [8] 0 0
Up to approximately 3 years
Secondary outcome [9] 0 0
Time to Response (TTR), by BICR per RECIST v1.1
Timepoint [9] 0 0
Up to approximately 3 years
Secondary outcome [10] 0 0
Objective Response Rate (ORR) by Investigator per RECIST v1.1
Timepoint [10] 0 0
Up to approximately 3 years
Secondary outcome [11] 0 0
DOR by Investigator per RECIST v1.1
Timepoint [11] 0 0
Up to approximately 3 years
Secondary outcome [12] 0 0
DCR by Investigator per RECIST v1.1
Timepoint [12] 0 0
Up to approximately 3 years
Secondary outcome [13] 0 0
TTR by Investigator per RECIST v1.1
Timepoint [13] 0 0
Up to approximately 3 years
Secondary outcome [14] 0 0
Progression Free Survival (PFS) by BICR and Investigator per RECIST v1.1
Timepoint [14] 0 0
Up to approximately 3 years
Secondary outcome [15] 0 0
Overall Survival
Timepoint [15] 0 0
Up to approximately 3 years
Secondary outcome [16] 0 0
Number of Participants with Adverse Events (AEs)
Timepoint [16] 0 0
Up to approximately 3 years
Secondary outcome [17] 0 0
Change from Baseline in Functional Assessment of Cancer Therapy - Melanoma Subscale (FACT-MS)
Timepoint [17] 0 0
Up to approximately 3 years

Eligibility
Key inclusion criteria
Inclusion Criteria

* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of = 1/Lansky Performance Score = 80% for adolescents (= 12 to < 18 years of age).
* Participants must have histologically confirmed Stage III (unresectable) or Stage IV (metastatic) melanoma, per the American Joint Committee for Cancer (AJCC) staging system.
* Participants must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
* Participants must be = 12 years of age. Participants who are = 12 years of age and < 18 years of age (adolescents) must weigh = 40 kg at the time of signing the informed consent (assent).
* Participants must have histologically confirmed Stage III (unresectable) or Stage IV (metastatic) melanoma, per the AJCC staging system (8th edition).
Minimum age
12 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

* Participants must not have ocular melanoma.
* Participants must not have a history of myocarditis, regardless of etiology.
* Participants must not have a condition requiring systemic treatment with either corticosteroids (>10 milligrams [mg] daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses >10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
6/03/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
18/11/2027
Actual
Sample size
Target
570
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Local Institution - 0050 - Coffs Harbour
Recruitment hospital [2] 0 0
Local Institution - 0175 - Orange
Recruitment hospital [3] 0 0
Local Institution - 0172 - Port Macquarie
Recruitment hospital [4] 0 0
Local Institution - 0118 - Wagga Wagga
Recruitment hospital [5] 0 0
Local Institution - 0184 - Waratah
Recruitment hospital [6] 0 0
Local Institution - 0033 - Westmead
Recruitment hospital [7] 0 0
Local Institution - 0055 - Wollstonecraft
Recruitment hospital [8] 0 0
Local Institution - 0090 - Birtinya
Recruitment hospital [9] 0 0
Local Institution - 0008 - Bendigo
Recruitment hospital [10] 0 0
Local Institution - 0059 - Box Hill
Recruitment hospital [11] 0 0
Local Institution - 0154 - Heidelberg
Recruitment hospital [12] 0 0
Local Institution - 0030 - Melbourne
Recruitment hospital [13] 0 0
Local Institution - 0109 - Traralgon
Recruitment hospital [14] 0 0
Local Institution - 0106 - Nedlands
Recruitment hospital [15] 0 0
Local Institution - 0161 - Nedlands
Recruitment postcode(s) [1] 0 0
2450 - Coffs Harbour
Recruitment postcode(s) [2] 0 0
2800 - Orange
Recruitment postcode(s) [3] 0 0
2444 - Port Macquarie
Recruitment postcode(s) [4] 0 0
2650 - Wagga Wagga
Recruitment postcode(s) [5] 0 0
2298 - Waratah
Recruitment postcode(s) [6] 0 0
2145 - Westmead
Recruitment postcode(s) [7] 0 0
2065 - Wollstonecraft
Recruitment postcode(s) [8] 0 0
4575 - Birtinya
Recruitment postcode(s) [9] 0 0
3550 - Bendigo
Recruitment postcode(s) [10] 0 0
3128 - Box Hill
Recruitment postcode(s) [11] 0 0
3084 - Heidelberg
Recruitment postcode(s) [12] 0 0
3004 - Melbourne
Recruitment postcode(s) [13] 0 0
3844 - Traralgon
Recruitment postcode(s) [14] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
Nebraska
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Pennsylvania
Country [11] 0 0
United States of America
State/province [11] 0 0
Utah
Country [12] 0 0
United States of America
State/province [12] 0 0
Virginia
Country [13] 0 0
Austria
State/province [13] 0 0
Graz
Country [14] 0 0
Austria
State/province [14] 0 0
Salzburg
Country [15] 0 0
Austria
State/province [15] 0 0
St. Polten
Country [16] 0 0
Austria
State/province [16] 0 0
Wien
Country [17] 0 0
Belgium
State/province [17] 0 0
Brussels
Country [18] 0 0
Belgium
State/province [18] 0 0
Charleroi
Country [19] 0 0
Belgium
State/province [19] 0 0
Liege
Country [20] 0 0
Brazil
State/province [20] 0 0
Ce
Country [21] 0 0
Brazil
State/province [21] 0 0
ES
Country [22] 0 0
Brazil
State/province [22] 0 0
Minas Gerais
Country [23] 0 0
Brazil
State/province [23] 0 0
Rio Grande Do Sul
Country [24] 0 0
Brazil
State/province [24] 0 0
RIO Grande DO SUL
Country [25] 0 0
Brazil
State/province [25] 0 0
Sao Paulo
Country [26] 0 0
Brazil
State/province [26] 0 0
SC
Country [27] 0 0
Brazil
State/province [27] 0 0
Rio De Janeiro
Country [28] 0 0
Canada
State/province [28] 0 0
Alberta
Country [29] 0 0
Canada
State/province [29] 0 0
Ontario
Country [30] 0 0
Canada
State/province [30] 0 0
Quebec
Country [31] 0 0
Chile
State/province [31] 0 0
Araucania
Country [32] 0 0
Chile
State/province [32] 0 0
Los Lagos
Country [33] 0 0
Chile
State/province [33] 0 0
Metropolitana
Country [34] 0 0
Chile
State/province [34] 0 0
Providencia
Country [35] 0 0
Chile
State/province [35] 0 0
Valparaiso
Country [36] 0 0
Chile
State/province [36] 0 0
Santiago
Country [37] 0 0
Czechia
State/province [37] 0 0
NY
Country [38] 0 0
Czechia
State/province [38] 0 0
Hradec Kralove
Country [39] 0 0
Czechia
State/province [39] 0 0
Olomouc
Country [40] 0 0
Czechia
State/province [40] 0 0
Ostrava Poruba
Country [41] 0 0
Czechia
State/province [41] 0 0
Prague
Country [42] 0 0
Finland
State/province [42] 0 0
Helsinki
Country [43] 0 0
Finland
State/province [43] 0 0
Tampere
Country [44] 0 0
Finland
State/province [44] 0 0
Turku
Country [45] 0 0
France
State/province [45] 0 0
Cedex 9
Country [46] 0 0
France
State/province [46] 0 0
Ile De France
Country [47] 0 0
France
State/province [47] 0 0
Indre-Et-Loire
Country [48] 0 0
France
State/province [48] 0 0
Nord
Country [49] 0 0
France
State/province [49] 0 0
OH
Country [50] 0 0
France
State/province [50] 0 0
Val-De-Marne
Country [51] 0 0
France
State/province [51] 0 0
Amiens
Country [52] 0 0
France
State/province [52] 0 0
Bayonne
Country [53] 0 0
France
State/province [53] 0 0
Bordeaux
Country [54] 0 0
France
State/province [54] 0 0
Clermont Ferrand Cedex 1
Country [55] 0 0
France
State/province [55] 0 0
Dijon
Country [56] 0 0
France
State/province [56] 0 0
Marseille
Country [57] 0 0
France
State/province [57] 0 0
Pierre-Benite
Country [58] 0 0
France
State/province [58] 0 0
Rennes Cedex
Country [59] 0 0
France
State/province [59] 0 0
Rouen
Country [60] 0 0
Germany
State/province [60] 0 0
Baden-Wurttemberg
Country [61] 0 0
Germany
State/province [61] 0 0
Bayern
Country [62] 0 0
Germany
State/province [62] 0 0
Schleswig-Holstein
Country [63] 0 0
Germany
State/province [63] 0 0
Berlin
Country [64] 0 0
Germany
State/province [64] 0 0
Buxtehude
Country [65] 0 0
Germany
State/province [65] 0 0
Dortmund
Country [66] 0 0
Germany
State/province [66] 0 0
Erfurt
Country [67] 0 0
Germany
State/province [67] 0 0
Essen
Country [68] 0 0
Germany
State/province [68] 0 0
Frankfurt am Main
Country [69] 0 0
Germany
State/province [69] 0 0
Giessen
Country [70] 0 0
Germany
State/province [70] 0 0
Goettingen
Country [71] 0 0
Germany
State/province [71] 0 0
Hamburg
Country [72] 0 0
Germany
State/province [72] 0 0
Ludwigshafen
Country [73] 0 0
Germany
State/province [73] 0 0
Marburg
Country [74] 0 0
Germany
State/province [74] 0 0
Minden
Country [75] 0 0
Germany
State/province [75] 0 0
Nuernberg
Country [76] 0 0
Germany
State/province [76] 0 0
Rostock
Country [77] 0 0
Germany
State/province [77] 0 0
Tuebingen
Country [78] 0 0
Israel
State/province [78] 0 0
Afula
Country [79] 0 0
Israel
State/province [79] 0 0
Jerusalem
Country [80] 0 0
Israel
State/province [80] 0 0
Petah-Tikvah
Country [81] 0 0
Israel
State/province [81] 0 0
Tel Hashomer
Country [82] 0 0
Israel
State/province [82] 0 0
Tel-Aviv
Country [83] 0 0
Italy
State/province [83] 0 0
Bari
Country [84] 0 0
Italy
State/province [84] 0 0
Genova
Country [85] 0 0
Italy
State/province [85] 0 0
Milan
Country [86] 0 0
Italy
State/province [86] 0 0
Napoli
Country [87] 0 0
Italy
State/province [87] 0 0
Perugia
Country [88] 0 0
Italy
State/province [88] 0 0
Roma
Country [89] 0 0
Italy
State/province [89] 0 0
Siena
Country [90] 0 0
Norway
State/province [90] 0 0
Bodo
Country [91] 0 0
Norway
State/province [91] 0 0
Gralum
Country [92] 0 0
Norway
State/province [92] 0 0
Lørenskog
Country [93] 0 0
Norway
State/province [93] 0 0
Oslo
Country [94] 0 0
Poland
State/province [94] 0 0
Kujawsko-pomorskie
Country [95] 0 0
Poland
State/province [95] 0 0
Malopolskie
Country [96] 0 0
Poland
State/province [96] 0 0
Opolskie
Country [97] 0 0
Poland
State/province [97] 0 0
Wiekopolskie
Country [98] 0 0
Poland
State/province [98] 0 0
Warszawa
Country [99] 0 0
Spain
State/province [99] 0 0
Gipuzkoa
Country [100] 0 0
Spain
State/province [100] 0 0
A Coruna
Country [101] 0 0
Spain
State/province [101] 0 0
Badalona
Country [102] 0 0
Spain
State/province [102] 0 0
Barcelona
Country [103] 0 0
Spain
State/province [103] 0 0
Jaen
Country [104] 0 0
Spain
State/province [104] 0 0
Las Palmas de Gran Canaria
Country [105] 0 0
Spain
State/province [105] 0 0
Madrid
Country [106] 0 0
Spain
State/province [106] 0 0
Sevilla
Country [107] 0 0
Spain
State/province [107] 0 0
Valencia
Country [108] 0 0
Sweden
State/province [108] 0 0
Stockholm
Country [109] 0 0
Sweden
State/province [109] 0 0
Lund
Country [110] 0 0
Switzerland
State/province [110] 0 0
Bern
Country [111] 0 0
Switzerland
State/province [111] 0 0
Chur
Country [112] 0 0
Switzerland
State/province [112] 0 0
Lausanne
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Greater London
Country [114] 0 0
United Kingdom
State/province [114] 0 0
Oxfordshire
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Tyne And Wear

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Address 0 0
Country 0 0
Phone 0 0
855-907-3286
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT05625399